FDA Okays New J&J Hepatitis C Drug for Safety and 2 Other Dow Movers to Watch

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Johnson & Johnson (NYSE:JNJ): Current price $92.14

On Tuesday, FDA reviewers said that Johnson & Johnson’s new hepatitis C drug indicated an acceptable safety profile in clinical trials. The drug, simeprevir, was evaluated in combination with standard hepatitis C drugs, peginterferon-alpha, and ribavirin in adult patients who had failed prior interferon-based therapy or had not received any medication. The reviewers announced that the drug would be categorized as a “Pregnancy Category C” in labeling, meaning that the potential benefits of the drug may indicate its use for pregnant women, even though animal trials showed the drug had a few adverse effects on a fetus.

jnj-20131022

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business